The role of gene fusions in amyotrophic lateral sclerosis

Active Grant Awarded

Award ID
RNS146186ULL226
Recipient
Awarding agency
Obligated
$654,784

Award facts

Completion date 0% complete
Place of performance
Charlestown, MA 02129, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Institute of Neurological Disorders and Stroke awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $654,784 on November 19, 2026, under Neurosciences and Neurological Disorders – Research Projects (RP), CFDA 93.NS1, as a grant (Grant RNS146186ULL226). The award funds research on the role of gene fusions in amyotrophic lateral sclerosis (ALS). The project hypothesizes that RNA-based fusion transcripts arise from aging- and stress-associated RNA-binding protein dysregulation, are translated, and function as mechanistically active modifiers of neuronal dysfunction in ALS. Aim 1 defines the upstream mechanisms driving ALS-specific fusion formation by examining the roles of aging, cellular stress, and RNA-binding proteins through long-read sequencing and perturbation approaches in human neuronal models. The award's ultimate completion date is November 30, 2031, and place of performance is Charlestown, MA 02129. The federal program supports NINDS extramural research into the fundamental structure and function of the brain and nervous system. The source identifies no sub-recipients.

Description

Abstract
There is a fundamental lack of understanding of the mechanisms underlying neurological diseases that slows research progress and hampers drug development. This knowledge void is particularly acute for amyotrophic lateral sclerosis (ALS), a severe neurodegenerative disease leading to death within 2-5 years from diagnosis, in which the precise molecular drivers of neuronal vulnerability remain incompletely defined. Although several causal loci have been identified and genetic risk contributes to ALS disease architecture, the etiology of >80% of cases remains unexplained by conventional molecular genetic approaches. Recent transcriptomic studies have revealed widespread RNA MIS-splicing and transcript instability in ALS; however, structural rearrangements at the RNA level have not been systematically interrogated. Gene fusions are formed when two independent genes become juxtaposed and can generate chimeric transcripts and proteins with altered function. While fusion events are well established as pathogenic drivers in cancer, their relevance in neurodegeneration remains largely unexplored. Our recent published findings demonstrate a significant enrichment of ALS-specific RNA fusions in post-mortem CNS tissue that are not explained by underlying genomic structural variants, suggesting a transcriptional origin. We therefore hypothesize that RNA-based fusion transcripts arise from aging- and stress-associated RNA-binding protein dysregulation, are translated, and function as mechanistically active modifiers of neuronal dysfunction in ALS. Our specific aims are designed to test this hypothesis. In aim 1, we will define the upstream mechanisms driving ALS-specific fusion formation by interrogating the roles of aging, cellular stress, and RNA-binding proteins using long- read sequencing and perturbation approaches in human neuronal models. In aim 2, we will determine whether prioritized fusion transcripts engage ribosomes, generate detectable peptides, and exhibit cell-type specificity in ALS tissue and patient- derived systems. In aim 3, we will directly test the functional consequences of recurrent, long-read-validated fusion transcripts in human motor neurons and multi-lineage organoid models. Together, these studies will establish whether ALS- specific RNA fusions represent biologically active contributors to neuronal dysfunction and define a systematic framework for evaluating transcript-level structural abnormalities as therapeutic targets in ALS. 1

Quick answers

Who received award RNS146186ULL226?

RNS146186ULL226 was awarded to The General Hospital Corporation by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on November 19, 2026.

How much is award RNS146186ULL226 worth?

$654,784 has been obligated on RNS146186ULL226.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award